◈ Nootpedia
Compact view
Research pass: thorough Peptide · Injectable WATCH-LIST LOW-MEDIUM

Epithalon (Epitalon / Epithalamin tetrapeptide)

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict WATCH-LIST LOW-MEDIUM

Mechanistically interesting and remarkably clean safety profile across decades of Russian use, BUT: (a) ~all pivotal evidence is single-lab (Khavinson/Anisimov, St. Petersburg Institute of Bioregulation and Gerontology) with 196 group-held patents, commercial sales conflict, and no NIA-ITP-grade replication; (b) the use-case for a 20yo with already-near-peak telomere length is theoretically weak — telomere attrition is plateaued in young adulthood, the Russian cohort data is in 60-80yo subjects; (c) the "receptor priming for downstream peptides" rationale Dylan flagged is a vendor/community claim, not directly proven; (d) Western academic uptake remains near-zero. **Would upgrade to OPTIONAL-ADD if:** an independent Western lab publishes telomerase activation replication in primary human cells (one such 2025 paper exists — see Evidence section, but author affiliation needs vetting); or if Dylan's Phase 3 (post-30) longevity protocol moves into actual implementation. **For now: park on watch-list; revisit at age 25-30 or when independent replication firms up.**

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    WATCH-LIST

    LOW-MEDIUM confidence. - Telomere attrition is at lifetime plateau; pineal melatonin output is near peak. The published evidence is in 60-80yo subjects, and the 20yo extrapolation has zero direct trial evidence. The "receptor priming for downstream peptides" rationale is community/vendor framing, not published mechanism. Park on watch-list; revisit at 25-30 or when independent Western replication firms up. - What would change verdict to OPTIONAL-ADD: an independent Western lab publishes telomerase activation replication in primary human cells with rigor; Dylan's chronotype-migration hits a wall and pineal-melatonin restoration becomes a specific use case; or Dylan moves into formal Phase 3 longevity protocol planning post-25.

  • 30-50, executive maintenance
    OPTIONAL-ADD

    LOW confidence. - This is the demographic where the longevity-protocol case starts to make more sense — telomere attrition resumes, pineal output starts declining around 40, sleep architecture changes. Reasonable as 1×/year cycle with biomarker tracking. Not a daily intervention. Stronger case if family history of premature aging / cardiovascular / cancer mortality.

  • 50+, mild cognitive decline
    STRONG-CANDIDATE

    LOW-MEDIUM confidence. - Best-fit demographic per Khavinson framework. The 266-subject elderly cohort is exactly this population. Mortality-reduction signal is large (1.6-4.1×) but single-source. Reasonable to run 1-2 cycles/year as part of broader longevity protocol if combined with proper bloodwork, sleep tracking, and (ideally) longitudinal biomarker (LTL, epigenetic age, melatonin). The one population where the evidence-claim and use-case actually overlap.

  • Anxiety-prone
    OPTIONAL-ADD

    with caution. - Not an anxiolytic, but reported sleep + mood effects could be supportive. Vivid dreams could be problematic for some anxiety profiles. Selank, L-theanine, magnesium are higher-yield first-line.

  • High athletic load, tested status (WADA)
    WATCH-LIST

    - Epitalon is NOT currently on WADA Prohibited List as of 2026. That's a moving target — peptide bioregulators get reclassified periodically. Verify before any sanctioned competition. Theoretical risk that growth-promoting / cellular-immortalization compounds get reclassified. For tested combat athletes: not a primary stack item but worth checking.

  • Sleep-disordered (DSPD, insomnia, fragmented sleep)
    OPTIONAL-ADD

    with thoughtful trial. - Strongest non-elderly use case. If aging-pineal-pattern sleep dysfunction is the issue (low nocturnal melatonin, fragmented sleep, advanced sleep phase), restoring endogenous melatonin synthesis is biologically reasonable. The 75-women circadian study shows this works in middle-aged women (not very old). For Dylan's late chronotype: theoretical fit, but lower-yield than behavioral chronotherapy + light scheduling first. If post-V5 the chronotype migration hits a wall, then test.

  • Recovery-focused (post-injury, post-illness)
    OPTIONAL-ADD

    - Not a tissue-repair peptide (BPC-157 / TB-500 own that). Useful as part of a broader stack if recovery is plateaued and sleep architecture is the limiter. Not primary.

  • Strength/anabolic-focused
    SKIP-FOR-NOW

    (wrong category). - Not anabolic. Not the right tool for that axis. GH-axis peptides + creatine + protein hit strength.

  • Longevity-protocol-focused (Phase 3 archetype, 25-50yo)
    STRONG-CANDIDATE

    per Khavinson framework, MEDIUM-LOW confidence per evidence. - This is the actual archetype the compound was designed for in modern Western longevity practice. The mechanistic framework (pineal-thymus axis restoration, telomerase activation, circadian normalization) is intellectually consistent with what 35-50yo longevity-focused users want. Reasonable as 1-2 cycles/year + biomarker tracking. Acknowledge the single-source evidence honestly.

▸ Subjective experience (deep)

Most users — including healthy-baseline ones — report subtle to none as the dominant first-cycle experience. The compound is not a stimulant, not a mood lifter in the bupropion sense, not a sleep aid in the trazodone sense. The reported experience pattern:

  • Days 1–3: Most users feel nothing. Some report a mild "settled" feeling on the second or third evening dose; a few report mild flu-like symptoms or temporary fatigue (interpreted as circadian rhythm adjusting).
  • Days 4–10: Sleep deepening starts to show up — quicker onset, fewer mid-night wakeups, more vivid dreams (the most consistent subjective marker; consistent with restored REM cycling and elevated nocturnal melatonin). Some report "mood-bright" or "calm-clear" effects.
  • Days 10–20: Cumulative deepening of the sleep + dream pattern. A subset reports improved morning energy / less-foggy waking. A subset reports nothing different.
  • Post-cycle (weeks 1–8): Reported residual benefit — sleep architecture stays improved for weeks-months in responders. This long tail is the actual point: like Cerebrolysin, you're not chasing an on-cycle peak, you're investing in baseline restoration.

Honesty about variability: "Felt nothing" is a common report, especially in young healthy users whose pineal output is already near peak. The compound was designed for aging pineals. A 70yo with a calcified, melatonin-poor pineal has somewhere to go. A 20yo who already sleeps 7-8 hours and falls asleep fine has much less. Set expectation: Dylan likely feels little to nothing on first cycle, and the case for running it is mechanistic / preventive, not subjective-effect-driven.

Vivid dreams are real and worth flagging — Dylan migrating his sleep schedule to midnight and using L-Tryptophan pre-bed already has a melatonin-supporting setup. Adding Epitalon may produce notably more dream activity (interesting / pleasant for most; rarely disruptive). If dreams become bothersome, AM dosing instead of evening helps.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Not a stim-tolerance compound. The bioregulator framework explicitly assumes that pulsed dosing > continuous, with the system needing months to "reset" between cycles. No documented receptor downregulation in the way amphetamines downregulate D2.
  • Recommended cycle: 5–10 mg SC × 10–20 d, then 4–6 months off. 1–2 cycles/year is the typical longevity-clinic protocol; some Russian protocols do annual 20-day courses indefinitely.
  • Reset protocol: No reset needed; if discontinuing entirely, no taper.
  • Long-term cycle stacking: Multi-year cycle programs (1-2×/year × 10+ years) are the design pattern in Khavinson protocols. No published data on what happens at 20+ years of repeated cycling.
▸ Stacking deep dive

Synergistic with (claimed / community / mechanistic)

  • thymalin / thymulin (T-prep peptides) — The original Khavinson stack. The 266-subject cohort showed largest mortality reduction with epithalamin + thymalin combination. Mechanism: pineal-thymus axis; pineal restores melatonin, thymus restores T-cell function, both restore immune-aging. Most evidenced stack. RUPharma + cosmicnootropic both stock thymalin. For Dylan: not relevant at 20 — thymic involution isn't a 20yo problem.
  • mots-c — Mitochondrial peptide. Community framing: epitalon "primes" cellular receptor sensitivity, MOTS-c then drives mitochondrial biogenesis. No published mechanism for the priming claim. Theoretical compatibility based on different molecular targets; no antagonism known.
  • nad-plus / NMN / NR — Sirtuin substrate restoration. Stacks logically with telomerase activation (sirtuins also influence telomere maintenance via SIRT6). Community-popular pairing in longevity protocols. No direct synergy data; no antagonism.
  • ss-31 (elamipretide) — Mitochondrial cardiolipin-targeted peptide. Different molecular layer than epitalon (mitochondrial membrane stabilization vs nuclear telomerase). Plausible additive logic, no direct stack data.
  • bpc-157 / tb-500 — Healing peptides. No direct mechanistic overlap; safe to co-administer per community use; no published interaction studies.
  • dsip (delta sleep-inducing peptide) — Combined "deep sleep" stack popular in peptide community. DSIP for sleep onset, epitalon for melatonin restoration. Both pineal-axis. Safe co-administration per community use; no published trials on the combination.
  • ghk-cu — Skin / wound / generalized anti-aging copper-tripeptide. No mechanistic conflict; commonly stacked. Different indication.

Avoid stacking with

  • Active cancer treatment — see Contraindications. Theoretical risk of telomerase activation in residual transformed cells.
  • Strong immune-modulating drugs (chemotherapy, immunosuppressants like cyclosporine, biologics) — insufficient data; unpredictable interaction.
  • Long-term high-dose exogenous melatonin (>3 mg/night chronic) — theoretical: if epitalon is restoring endogenous melatonin synthesis, simultaneous chronic high-dose exogenous melatonin may suppress the very pathway you're trying to restore (negative feedback on AANAT / pCREB). For Dylan's planned L-Tryptophan 1 g pre-bed (precursor for melatonin synthesis, not direct melatonin) this concern doesn't apply.

Neutral / safe co-administration

  • All V4 daily core supplements
  • Modafinil, bromantane, semax, NASA, Adamax (no documented interactions)
  • Cerebrolysin (different cycling calendar; both peptides; no documented interaction)
  • Selegiline (no documented MAO interaction; epitalon has no monoamine oxidase activity)
  • Creatine, beta-alanine, electrolytes, fish oil, NAC, magnesium
▸ Drug interactions deep dive
  • CYP enzymes: Epitalon is a tetrapeptide cleared by general peptidases. No documented CYP induction or inhibition. Does not affect modafinil (CYP3A4), selegiline (CYP2B6/3A4), bupropion (CYP2B6) metabolism.
  • Hormonal contraceptives: No interaction documented (irrelevant for Dylan).
  • Anticoagulants / antiplatelets: No documented interaction.
  • MAOIs: No mechanism for interaction (not a monoamine compound). Selegiline at low dose is fine to co-run.
  • SSRIs / SNRIs: No mechanism for interaction. Theoretical pineal/melatonin effect could amplify trazodone-like sedation in someone already on a sedating antidepressant — not relevant for Dylan.
  • Alcohol: No interaction (Dylan alcohol-free anyway).
  • Caffeine, nicotine: No interaction.
▸ Pharmacogenomics

Minimal data specifically for epitalon. The peptide is metabolized by general peptidases; no single CYP polymorphism alters its profile.

Indirect relevance worth checking on Dylan's 23andMe pull (June 2026):

  • TERT / TERC variants (telomere maintenance machinery) — if Dylan has a TERT variant associated with shorter baseline telomere length, the case for telomerase-activating intervention is theoretically stronger. Most TERT variants are rare and not on standard 23andMe panels; would need WGS or specialty panel.
  • MTNR1A / MTNR1B (melatonin receptor 1A/1B variants) — affects melatonin receptor sensitivity. If Dylan has variants reducing melatonin signaling, restoring endogenous melatonin synthesis is theoretically more impactful. Some 23andMe variants are reported.
  • AANAT polymorphisms — rate-limiting melatonin-synthesis enzyme. Less commonly genotyped on consumer panels.
  • CLOCK / BMAL1 / PER / CRY family circadian genes — affect circadian rhythm function. Late chronotype (Dylan-relevant) has heritable contribution. If Dylan has clear genetic late-chronotype markers, the pineal/melatonin restoration use case becomes more relevant — but this is exploratory, not actionable.

Action item post-23andMe: Pull MTNR1A/MTNR1B + circadian gene cluster. If anything pops, slightly increases the case for trying epitalon during the chronotype-migration phase. Otherwise no change.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Gray-market (preferred) RUPharma (rupharma.com) $168 / 50 mg pack (5 × 10 mg vials) high Russian-origin pharmacy. White lyophilized powder for IM/SC injection. 99%+ purity claimed (some batches reported as 99.92%). Expiry typically 12.2029. Dubai-reship post-2022 logistics. Reconstitute each vial with 2 mL sterile water; recommended dose 2.5–5 mg/d × 30–50 d.
Gray-market (preferred) CosmicNootropic (cosmicnootropic.com) similar tier (~$150–200/pack) when in stock high Same Russian-origin product line. Also stocks Epitalon Spray (Nanopep, sublingual / oral spray, 20 mL) — convenient but lower bioavailability. Stock intermittent.
Research-chem (US-domestic) Peptide Sciences, Edge Peptides, Biolongevity Labs, Cosmic Peptides, Paramount, Evolve, BioPure, Verified Peptides, Amino USA $50–$100 per 50 mg vial; bulk packs 10 vials × 50 mg ~$490 medium-high Lyophilized synthetic peptide marketed as "research only / not for human use." Verify COA + HPLC purity (target >98%) + endotoxin (<0.5 EU/mg). Different supply chain from Russian product — quality varies by vendor. Check third-party COA. Use only if Russian vendors out of stock or ship blocked.
US compounding pharmacies (formerly) Various (Empower, Tailor Made, etc., pre-2023) ~$200–600 / cycle n/a Effectively closed. FDA placed Epitalon on Category 2 list Sept 2023. Status fluid: nominator-withdrawn, scheduled for PCAC review July 24, 2026; may reopen if reclassified back to Category 1. As of 2026-05-05, US compounding access is restricted.
Telehealth peptide clinics Various (Beverly Hills Rejuvenation Center, Lyfe Medical, concierge longevity practices) $300–$1,500 / cycle medium Marketing-heavy. Often using research-grade reconstituted peptide, not Russian-origin product. Pricey relative to direct gray-market.
Travel pharmacy (Russia, EU) International Rx $20–50 / pack very high Standard Russian peptide-bioregulator pharmacy product. Cannot be shipped to US legally; travel-purchase only.

Cost math for Dylan (if he ever ran it):

  • Per cycle (5 mg SC × 20 d): 100 mg total = 2 packs of RUPharma (50 mg / pack) at $168 each = ~$336 / cycle
  • 2 cycles/year: ~$672 / year
  • Amortized: ~$56/month
  • Cheaper option using research-chem (Edge / Paramount, 50 mg vials at ~$50): ~$200-400/year amortized
  • Cosmic spray (sublingual): cheaper per mg but bioavailability adjustment makes it less cost-effective

Sourcing strategy if/when running:

  • Order 6-8 weeks before cycle start (Russia → US Dubai-reship 14-28 days)
  • Stock 1 cycle ahead
  • Cold chain: lyophilized powder is shelf-stable at room temp short-term but store refrigerated (2–8°C) for long-term. After reconstitution with bacteriostatic water, refrigerate and use within 30 days; with sterile water, use within 7 days.
  • Verify vial integrity, lyophilized cake appearance (white, no discoloration), expiry date >12 months out

Quality verification on receipt:

  • Lyophilized cake should be white, intact (not collapsed / oily looking)
  • Vial seal intact, no cracks
  • After reconstitution: clear solution, no particulates
  • COA from vendor for that lot if research-chem source
▸ Biomarkers to track (deep)

Baseline (before first cycle, if Dylan ever runs it)

  • CBC, CMP, lipid, hsCRP, IL-6, IGF-1 — V4 baseline (already planned June 2026)
  • Leukocyte telomere length (LTL) — if running specifically for telomere maintenance, get a baseline. Available via TelomereLengthTest.com, SpectraCell, Life Length, TruDiagnostic add-on. Caveat: single-test LTL is noisy — Dylan's GENETICS-SNAKE-OIL.md file already flags this. Multi-timepoint trending over years is the only signal that means anything; even then, the 2025 TA-65 meta-analysis showed telomere elongation didn't translate to functional improvements.
  • Epigenetic age (TruDiagnostic, Tally Health) — better-quality biological-age proxy than LTL. ±2-4 year noise per test; multi-timepoint trending matters.
  • Nocturnal salivary melatonin OR overnight 6-sulfatoxymelatonin (urine) — direct measure of pineal output. Most clinically interpretable biomarker for the circadian/pineal mechanism. Available via specialty labs.
  • Sleep architecture baseline (Oura, Whoop, Eight Sleep, or PSG) — REM %, deep sleep %, sleep onset latency, awakenings.
  • 23andMe pull (June 2026) — MTNR1A/1B, circadian gene cluster, any TERT/TERC info available.
  • Cognitive baseline (CNS Vital Signs, Cambridge Brain Sciences) — already establishing for Cerebrolysin; same baseline serves epitalon assessment.

During use

  • Days 1, 5, 10, 15, 20: Subjective log (sleep, dreams, mood, energy, injection-site)
  • Daily Oura/Whoop tracking — REM %, deep %, HRV, resting HR — the most accessible objective signal
  • Adverse event log — any GI, mood, allergic, dream-disturbance signal

Post-cycle (if cycled)

  • 2-4 weeks post-cycle: Repeat sleep architecture trend (Oura/Whoop summary). Repeat cognitive battery if it was anchored to this trial.
  • 3 months post-cycle: Repeat melatonin assay (salivary or urinary 6-SMT) to capture sustained restoration signal.
  • Annually (after 2-4 cycles): Repeat LTL or epigenetic age IF using as primary outcome biomarker. Acknowledge noise.

For Dylan honestly: the biomarker case for running this at 20 is weak. LTL is too noisy at single-test resolution, epigenetic age is in early days for tracking intervention effect at age 20, and the most actionable signal (sleep architecture / melatonin) is something Dylan already has multiple cleaner levers for (chronotype migration, L-Tryptophan, light hygiene). The biomarker stack is well-developed for older users — but for Dylan, it's stacking expensive measurements on top of a thin signal-to-noise.

▸ Controversies / open debates Live debate
  • The Khavinson "bioregulator" framework legitimacy. The central claim — that short peptides (2-7 amino acids, often with no obvious cell-surface receptor) cross cell membranes, enter the nucleus, bind DNA in a sequence-specific way, and modulate gene expression — is not part of mainstream molecular biology. Standard textbook biology says (a) most short peptides don't enter cells without specific transporters, (b) DNA-binding requires either specific protein domains or specific structural features that random tetrapeptides don't have, (c) tissue-specific gene regulation by free-floating peptides is mechanistically implausible without receptor mediation. Khavinson's group has published evidence for direct DNA / chromatin binding (H1 histone interaction, ATTTC motif binding), but this evidence has not been replicated by independent Western structural biology / molecular biology labs at the level required to upgrade it from "interesting but anomalous" to "established mechanism." Honest position: the framework is either a real biological discovery that Western science is slow to adopt, OR it's a partial truth (some of the peptides do something, some don't, mechanism is different than claimed, single-lab-bias inflates effects), OR it's nearly all noise + commercial promotion. The range of possibilities is wide, and the marketing tends to flatten it to "decades of Russian science prove this works." Be careful with that flattening.
  • 196 patents + commercial sales by the patenting group. Khavinson's St. Petersburg Institute holds 196+ patents on peptide bioregulators. The same group manufactures and sells the products. Same group does (most of) the research. This is the textbook setup for inflated effect sizes — see TA-65 case where 2025 meta-analysis found industry-sponsored trials inflated efficacy 2-3× vs independent. Without an independent replication track record, the conflict of interest cannot be controlled for.
  • The 2003 Khavinson + Morozov 266-subject mortality study specifically. Effect sizes (1.6× to 4.1× mortality reductions in 6-12 years) are enormously large — larger than statins, larger than smoking cessation, larger than most clinical interventions in modern medicine. Effects this large in a single trial should trigger the same skepticism we apply when a single drug trial shows a 50% mortality reduction in cancer. Either the underlying biology is among the strongest geroprotective signals ever documented, OR the trial methodology / data integrity has issues that wouldn't survive Western peer review. There is no way to know without independent replication, which has not happened in 22 years.
  • 2025 PMC paper (Epitalon increases telomere length in human cell lines). A potentially important Western mechanistic replication. I was unable to verify author affiliation in available searches — needs follow-up. If this paper is from an independent lab, it's the strongest non-Khavinson evidence for mechanism. If it's from Khavinson collaborators using Western co-authors as front, it's not real replication. Open task.
  • FDA Category 2 listing 2023 + nominator-withdrew + PCAC review 2026. The FDA's stated concern was potential immunogenicity, not efficacy fraud. The nominator-withdrawal mechanism by which 14 peptides (incl. Epitalon, GHK-Cu, MOTS-c, Thymosin Alpha-1) are scheduled to move back to Category 1 is not an FDA endorsement — it's a procedural retreat. PCAC consultation in July 2026 will determine final status. For Dylan: ignore the regulatory football, focus on actual biology. Compounded peptides may or may not be available domestically again post-July 2026; gray-market international remains.
  • The "receptor priming" claim Dylan flagged from external source. The framing that Epitalon should be run first in a longevity peptide stack to "prime" downstream peptide receptors (MOTS-c, NAD+, SS-31) is not in any published Khavinson paper or Western trial. It's a community / longevity-clinic framing. The mechanistic basis offered (epitalon "restores homeostatic responsiveness, allowing other peptides to work better") is plausible-sounding but unfalsifiable in the form it's usually stated. Treat as marketing-tier reasoning until shown otherwise.
  • Wikipedia banner: "fringe theories without giving appropriate weight to mainstream views." Wikipedia's epitalon article carries this tag. The reasonable interpretation: most editors trying to source the article find that the bulk of the citations are Khavinson-lab-internal, the magnitude of claimed effects vastly exceeds anything mainstream gerontology has published, and the article reads as advocacy rather than neutral summary. The tag itself is not evidence the compound doesn't work, but it's evidence that mainstream science does not currently treat the claims as established.
  • Epitalon paradox (telomerase activation but reduced tumor incidence in animals). Theoretically activating telomerase should increase cancer risk — telomerase is reactivated in 90% of cancers. Animal data shows the opposite (reduced spontaneous tumor incidence in epitalon-treated mice). The two non-mutually-exclusive resolutions are: (a) pulsed dosing → transient activation insufficient for tumorigenesis, (b) restored immune surveillance clears nascent tumors faster. Both are post-hoc explanations; neither has been rigorously tested. Dylan-relevant: at 20 with no cancer history, the absolute risk is very low either way; at 50+ with multi-decade cumulative dosing, the question is more pressing.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: WATCH-LIST (LOW-MEDIUM confidence).
    • Khavinson family was previously SKIP at encyclopedia level (Pinealon, Cortexin, Cerluten, Vesugen) due to single-source research, 196-patent conflict, zero independent replication, zero ClinicalTrials.gov entries. Epitalon is the strongest member of the family — it has the cleanest mechanism story (telomerase activation), the largest cohort study (266 subjects), and the most plausible biology (pineal melatonin restoration is real biology even if tetrapeptide mechanism is debated). Also has the only ~candidate Western mechanistic replication (2025 PMC12411320, affiliation TBD).
    • Re-evaluation context: the user-flagged "Phase 3 longevity protocol prime" framing deserves consideration but is community/vendor reasoning, not published mechanism. For a 20yo Dylan-archetype, the use case is mechanistically weak (telomeres at plateau, pineal at peak); for a Phase 3 30-50yo longevity-protocol archetype, the case is mechanistically reasonable but evidence-thin.
    • Net: WATCH-LIST is honest. SKIP would dismiss a compound with real (though contested) mechanistic story and clean safety profile. STRONG-CANDIDATE would overstate the evidence quality. Park on watch-list, revisit at 25-30 or when independent Western replication firms up.
▸ Open questions / gaps Open
  1. 2025 PMC12411320 author affiliation. Is this an independent Western replication of telomerase activation, or Khavinson-lab collaboration in Western journal? Critical for confidence-tier upgrade.
  2. NIA-ITP testing. Has the NIH Interventions Testing Program ever tested epitalon? If it's been submitted and rejected, why? If it's been submitted and is in queue, when does it read out? If never submitted, why not? (NIA-ITP is the gold-standard independent multi-site mouse longevity trial program; epitalon's absence from its track record is itself a signal.)
  3. Telomere maintenance over years in living humans (rigorous). No high-quality LTL trajectory data with proper assay (TeSLA, telomere shortest length assay) in epitalon-treated subjects across 5+ years. Khavinson cohort data is clinical-outcome based, not direct telomere trajectory.
  4. Optimal cycle frequency for non-elderly users. Russian protocols are designed around elderly subjects; cycle frequency for 25-50yo healthy users is extrapolation. Possibly 1×/year is sufficient; possibly 2×/year is overkill; no data.
  5. Subjective effect mechanism in young responders. When a 25-30yo non-pineal-degraded user reports clear sleep + dream effects from a cycle, what's actually happening? Is it placebo? Is there a non-pineal mechanism we're missing? Is it the histone-binding / epigenetic remodeling effect playing out subjectively?
  6. Cancer risk over multi-decade cycling. No human data on 20+ years of cycling. Theoretical concern given telomerase activation; animal data reassuring; long-tail unknown.
  7. 23andMe-actionable variants. Does MTNR1A/1B / circadian-cluster genotype actually predict response? No data; speculative.
  8. The "receptor priming" claim. Could this be tested? In principle, yes: a randomized trial of epitalon-then-MOTS-c vs MOTS-c-alone, with mitochondrial biomarker outcomes. Has not been done. Until then it's a community / vendor claim.
  9. PCAC review July 24, 2026. What does the FDA decide? Not biology, but affects US compounding sourcing pathway. Worth tracking if Dylan ever wants domestic compounded source vs Russian gray-market.
  10. Phase 3 Dylan protocol planning. When does Dylan formally move into "Phase 3 longevity protocol" mode? Probably mid-late 20s. At that point, re-pull this file and re-examine.
▸ Sources (full, with our context)
Back to compact view